Answers are grounded in this paper and cite their sources.
The insidious onset and aggressive nature of pancreatic cancer contributes to the poor treatment response and high mortality of this devastating disease. While surgery, chemotherapy and radiation have contributed to improvements in overall survival, roughly 90% of those afflicted by this disease will die within 5 years of diagnosis. The developed ablative locoregional treatment modalities have demonstrated promise in terms of overall survival and quality of life. In this review, we discuss some of the recent studies demonstrating the safety and efficacy of ablative treatments in patients with locally advanced pancreatic cancer.
No takes yet. Share an insight, caveat, or question.
Narayanan et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: